Tazarotene: Randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome

Cancer Prevention Research

Volumn 7, Issue 3, 2014, Pages 292-299

  Tang, Jean Y ^a,b   Chiou, Albert S ^b   Mackay Wiggan, Julian M ^d   Aszterbaum, Michelle ^c   Chanana, Anita M ^a   Lee, Wayne ^a   Lindgren, Joselyn A ^a   Raphael, Maria Acosta ^a   Thompson, Bobbye J ^d   Bickers, David R ^d   Epstein Jr , Ervin H ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; TAZAROTENE; DERMATOLOGICAL AGENT; NICOTINIC ACID DERIVATIVE;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREAM; DERMATITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRY SKIN; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SECONDARY ANALYSIS; SKIN ABRASION; SKIN EDEMA; SKIN IRRITATION; SKIN PRURITUS; TOPICAL TREATMENT; TUMOR VOLUME; CARCINOMA, BASAL CELL; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; BASAL CELL NEVUS SYNDROME; CARCINOMA, BASAL CELL; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC ACIDS; PHARMACEUTICAL VEHICLES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84897147027     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0305     Document Type: Article

References (30)

1. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353:2262-9. (Pubitemid 41697289)
2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
3. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2012; 133:1188-96.
4. DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012;132:785-96.
5. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987;66:98-113. (Pubitemid 17059640)
6. Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutan Med Surg 2011;30:S10-3.
7. 2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome. Dermatol Surg 2002;28:287-90.
8. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13:1933-8.
9. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002;43:269-73. (Pubitemid 35365416)
10. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-60. (Pubitemid 29191384)
11. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7.
12. Goldberg LH, Hsu SH, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol 1989;21:144-5. (Pubitemid 19171485)
13. Hodak E, Ginzburg A, David M, Sandbank M. Etretinate treatment of the nevoid basal cell carcinoma syndrome. Therapeutic and chemopreventive effect. Int J Dermatol 1987;26:606-9. (Pubitemid 17160093)
14. Kreul S, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, et al. A phase III cancer chemoprevention study of DMFO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res 2012;5:1368-74.
15. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8.
16. Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 2003;121:902-09. (Pubitemid 37239137)
17. Orlandi A, Bianchi L, Costanzo A, Campione E, Giusto Spagnoli L, Chimenti S. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol 2004;122:1037-41. (Pubitemid 38581007)
18. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999; 341:1767-8.
19. So PL, Lee K, Hebert J, Walker P, Lu Y, Hwang J, et al. Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation. Cancer Res 2004;64:4385-9. (Pubitemid 38856905)
20. So PL, Fujimoto MA, Epstein EH Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther 2008;7:1275-84.
21. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005;5:184-98. (Pubitemid 40314950)
22. Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Eilers D, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012;132: 1583- 90.
23. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. Clinical Manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997;69:209-308.
24. Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 2011;17: 3378-87.
25. Ling G, Ahmadian A, Persson A, Undén AB, Afink G, Williams C, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 2001;20:7770-8. (Pubitemid 33121950)
26. Reifenberger J, Wolter M, Knobbe CB, Köhler B, Schönicke A, Scharwächter C, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005; 152:43-51.
27. Weihrauch M, Bader M, Lehnert G, Wittekind C, Tannapfel A, Wrbitzky R. Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma. Int Arch Occup Environ Health 2002;75:272-6. (Pubitemid 36075113)
28. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat. 2003;21:217-28. (Pubitemid 36292964)
29. Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005;11: 971-81. (Pubitemid 40175744)
30. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54. (Pubitemid 44323701)